MEDICAL DEVICES RETURNS SUMMARY: The Fund Managers have been an active investor in the medical device sector across the New Leaf and Sprout Funds. Combined, the Fund Managers have invested $371 million in 29 medical device companies, and have gross realizations of $394 million and a 1.82x gross realized Multiple and 9.4% gross realized IRR. Table 3 summarizes the gross realized and unrealized returns from medical device investments in each New Leaf fund and the Sprout Funds: Table 3: Gross Medical Device Performance by Fund Group $ amounts in millions, as of March 31, 2014 Beane Deals Total Cost Total Realized Unrealized Realized Overall Realized Overall New Leaf Ventures II, L.P. (2008) 5 $72.0 $52.5 $1.8 $50.6 0.11x 0.73x N/A 9.2% New Leaf Ventures I, L.P. (2005) 6 $73.3 $146.4 $67.3 $79.2 5.64x 2.00x 58.8% 15.5% All Sprout Funds (1993, 1995, 1998, 2000) 18 $225.2 $328.9 $325.1 $3.7 1.73x 1.46x 8.3% 6.1% Total 29 $370.5 $527.8 $394.2 $133.5 1.82x 1.42x 9.4% 6.6% Please see the endnotes in Appendix 4 for definitions of terms and/or methodology. Note that these gross returns are for portions of each fund, broken out by investment sector subfocus. Management fees, the general partner's carried interest and other expenses are applied on a fund level and not based on individual investments or a portion of the investment portfolio. For net returns on each fund which would include these items, please see Appendix 2. TOOLS, DIAGNOSTICS, & INFRASTRUCTURE RETURNS SUMMARY: The Fund Managers have made investments in the tools, diagnostics, and infrastructure sector across the New Leaf and Sprout Group funds. The strategy has included predominantly later/commercial stage tools and infrastructure investments and a mix of early/development stage and later/commercial stage diagnostics companies over time. Combined, the Fund Managers have invested in 17 companies, for a total $221 million in cost. The Fund Managers have generated gross realizations of $261 million, for a 1.50x gro